|
|
Volumn 8 Suppl 2, Issue , 2007, Pages
|
|
Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CVAD PROTOCOL;
CYCLOPHOSPHAMIDE;
DEXAMETHASONE;
DOXORUBICIN;
MONOCLONAL ANTIBODY;
RITUXIMAB;
UNCLASSIFIED DRUG;
VINCRISTINE;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
BURKITT LYMPHOMA;
DISEASE FREE SURVIVAL;
DRUG COMBINATION;
FEMALE;
HUMAN;
MALE;
MANTLE CELL LYMPHOMA;
MIDDLE AGED;
PATHOLOGY;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BURKITT LYMPHOMA;
CYCLOPHOSPHAMIDE;
DEXAMETHASONE;
DISEASE-FREE SURVIVAL;
DOXORUBICIN;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMANS;
LYMPHOMA, MANTLE-CELL;
MALE;
MIDDLE AGED;
SURVIVAL RATE;
TEXAS;
TREATMENT OUTCOME;
VINCRISTINE;
MLCS;
MLOWN;
|
|
EID: 40949147480
PISSN: 15579190
EISSN: None
Source Type: Journal
DOI: 10.3816/CLM.2007.s.034 Document Type: Article |
|
Times cited : (44)
|
|
References (0)
|
